Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Labcorp Holdings Inc. (NYSE: LH), a global provider of innovative and comprehensive laboratory services. These documents offer detailed information about the company’s operations, financial condition, governance and material events.
Labcorp’s recent current reports on Form 8-K include disclosures about quarterly and annual financial results, updated guidance and capital allocation decisions such as cash dividends on its common stock. Other 8-K filings describe participation in investor conferences, appointments and retirements of directors and executives, and transactions affecting parts of its business, such as the sale of select early development medical device testing assets.
Filings also confirm that Labcorp’s common stock, with a par value of $0.10 per share, is registered under Section 12(b) of the Securities Exchange Act and trades on the New York Stock Exchange under the symbol LH. Segment information released through earnings-related filings outlines performance for the Diagnostics Laboratories and Biopharma Laboratory Services segments, providing context on demand for clinical testing and biopharma laboratory services.
On Stock Titan, Labcorp’s SEC filings are updated as they become available from EDGAR. AI-powered summaries help explain the key points in complex documents, so readers can quickly understand items such as results of operations, changes in leadership, dividend declarations and significant transactions. Users can review Forms 8-K for material events, as well as other core filings like annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials when they are filed.
For investors, analysts and other interested readers, this page serves as a focused entry point into Labcorp’s regulatory disclosures, combining real-time updates with AI-generated highlights to make the information easier to interpret.
Labcorp Holdings Inc. Chief Financial Officer and EVP Julia Aijun Wang exercised previously granted restricted stock units, receiving 860 shares of common stock on February 11, 2026. Each unit converts into one share of common stock.
To cover tax withholding obligations, 245 shares of common stock were withheld at a price of
Vaughn Bryan T reported multiple insider transaction types in a Form 4 filing for LH. The filing lists transactions totaling 739 shares at a weighted average price of $289.89 per share. Following the reported transactions, holdings were 4,031 shares.
Labcorp Holdings Inc. executive Sandra D. van der Vaart reported equity award activity and related tax withholding. On
After this conversion, her directly held common stock position was 3,225.4864 shares before tax withholding. To cover tax obligations, 99 shares of common stock were withheld at a price of
Labcorp Holdings Inc. executive Mark S. Schroeder, EVP, President Diagnostics & COO, reported equity award activity involving restricted stock units and common shares. On February 11, 2026, he converted 806 Restricted Stock Units into an equal number of common shares at an exercise price of $0 per share.
To satisfy tax withholding obligations, 259 common shares were withheld at a price of $289.89 per share. Following these transactions, Schroeder directly holds 6,473.1426 shares of Labcorp common stock and 2,358 Restricted Stock Units, which each represent the right to receive one share of common stock.
Labcorp Holdings Inc. President and CEO Adam H. Schechter reported several equity transactions dated February 11, 2026. He sold 5,273 shares of common stock in an open-market transaction at $284.38 per share under a Rule 10b5-1 trading plan.
On the same day, he acquired 3,656 shares of common stock through the exercise and conversion of Restricted Stock Units, and 1,521 shares were withheld to cover tax obligations. Following these transactions, he directly held 89,478 common shares and 22,214 Restricted Stock Units, each RSU representing the right to receive one share of common stock.
Labcorp Holdings Inc. executive Akinbolade Oyegunwa exercised restricted stock units and had shares withheld for taxes. On February 11, 2026, 230 restricted stock units converted into 230 shares of common stock. Of these, 68 shares were withheld to cover tax obligations at
Following these transactions, Oyegunwa directly held 4,106.253 shares of common stock and 2,190 restricted stock units. The vested units came from a grant scheduled to vest in three equal annual installments beginning on
Labcorp Holdings Inc. executive Jonathan C. Meltzer, EVP, Operations, reported several equity transactions in Labcorp common stock. On February 11, 2026, he acquired 243 shares of common stock through the vesting and conversion of 243 Restricted Stock Units, each RSU representing one share of common stock.
To cover taxes related to this vesting, 70 shares were withheld at a price of
Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported equity award activity on
Labcorp Holdings Inc. executive Anita Z. Graham reported routine equity award activity. On February 11, 2026, 356 Restricted Stock Units converted into 356 shares of common stock at an exercise price of $0. To cover tax withholding, 109 shares of common stock were withheld at $289.89 per share. After these transactions, Graham directly owned 1,460 shares of common stock and 2,401 Restricted Stock Units, which continue to vest in three equal annual installments starting February 11, 2026.
Labcorp Holdings Inc. executive Brian J. Caveney, EVP and President of Enterprise Diagnostics, CMO & CSO, reported equity award activity in company stock. On February 11, 2026, he exercised 740 Restricted Stock Units, converting them into 740 shares of Common Stock at an exercise price of $0 per share.
To cover tax withholding obligations related to this vesting, 211 shares of Common Stock were withheld at a price of $289.89 per share, coded as a disposition for tax payment rather than an open-market sale. After these transactions, he directly held 31,606.9234 shares of Common Stock and 4,170 Restricted Stock Units, which vest in three equal annual installments beginning on February 11, 2026.